OSE Immunotherapeutics Says its IBD Candidate OSE-127 Could Help Treatment-resistant Patients

OSE Immunotherapeutics Says its IBD Candidate OSE-127 Could Help Treatment-resistant Patients
OSE Immunotherapeutics presented promising data from preclinical experiments of its investigational treatment OSE-127 (Effi-7) for inflammatory bowel disease (IBD) at FOCIS 2017, the Federation of Clinical Immunology Societies, held June 14-17 in Chicago. The drug, an antibody that blocks the alpha chain of the interleukin-7 receptor (IL-7R), prevented T-cells (immune cells) from entering gut tissue both in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *